Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 Pipeline Review, H1 2018
Summary
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 Carcinoembryonic antigenrelated cell adhesion molecule 5 CEACAM5 also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen CEA family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Gastrointestinal which include indications Metastatic Colorectal Cancer, NonSmall Cell Lung Cancer, Adenocarcinoma, Colorectal Cancer, Crohn's Disease Regional Enteritis, Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Non Muscle Invasive Bladder Cancer NMIBC Superficial Bladder Cancer, Pancreatic Cancer, Peritoneal Tumor, Recurrent Glioblastoma Multiforme GBM and Solid Tumor.
The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Pipeline Review, H1 2018, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5
The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics and enlists all their major and minor projects
The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
NEXT ARTICLE